<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03051516</url>
  </required_header>
  <id_info>
    <org_study_id>9790</org_study_id>
    <secondary_id>NCI-2017-00151</secondary_id>
    <secondary_id>9790</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>R01CA213130</secondary_id>
    <secondary_id>RG1001522</secondary_id>
    <nct_id>NCT03051516</nct_id>
  </id_info>
  <brief_title>HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions</brief_title>
  <official_title>HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IV trial studies how well human papillomavirus (HPV) vaccine therapy works in&#xD;
      interrupting progression in patients with high-grade vulvar or anal lesions. Vaccines made&#xD;
      from HPV peptides or antigens may help the body build an effective immune response to kill&#xD;
      tumor cells and decrease the chance of vulvar or anal lesions to progress or come back.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive recombinant human papillomavirus nonavalent vaccine intramuscularly&#xD;
      (IM) at baseline, 2 months, and 6 months.&#xD;
&#xD;
      ARM II: Patients receive placebo IM at baseline, 2 months, and 6 months.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at months 7, 12, 18, 24, 36,&#xD;
      and 42.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">December 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to persistent high-risk infection among vaccine compared with placebo recipients</measure>
    <time_frame>Up to month 36</time_frame>
    <description>Persistence will be measured as two or more consecutive polymerase chain reaction positive swabs for the same human papillomavirus (HPV) genotype. Will use Cox proportional hazards to compare time start of interval for the persistent infection in the vaccinated to unvaccinated group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of anogenital high grade squamous intraepithelial lesion (HSIL)</measure>
    <time_frame>Up to month 36</time_frame>
    <description>Will compare vaccine and placebo recipients. Will evaluate differences in the hazard of recurrence using Cox proportional hazards in the intention to treat population and the per protocol population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) graded according to the Food and Drug Administration criteria</measure>
    <time_frame>Up to month 36</time_frame>
    <description>Will monitor safety by comparing type and frequency of AEs in the two study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV antibody level</measure>
    <time_frame>Up to month 36</time_frame>
    <description>Will evaluate placebo and vaccine recipients separately. Will assess whether presence and amount of HPV antibody, detected at baseline in the placebo arm, is protective against recurrence. For the vaccine arm, will assess whether magnitude of vaccine antibody levels month 1 following the third vaccination in the vaccine arm affects recurrence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>High Grade Anal Canal Intraepithelial Neoplasia</condition>
  <condition>Vulvar High Grade Squamous Intraepithelial Lesion</condition>
  <arm_group>
    <arm_group_label>Arm I (recombinant human papillomavirus nonavalent vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline, 2 months, and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo IM at baseline, 2 months, and 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (recombinant human papillomavirus nonavalent vaccine)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (recombinant human papillomavirus nonavalent vaccine)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Human Papillomavirus Nonavalent Vaccine</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm I (recombinant human papillomavirus nonavalent vaccine)</arm_group_label>
    <other_name>Gardasil 9</other_name>
    <other_name>Nonavalent HPV VLP Vaccine</other_name>
    <other_name>Recombinant HPV Nonavalent Vaccine</other_name>
    <other_name>Recombinant Human Papillomavirus 9-valent Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of initial or recurrent anal or vulvar high-grade&#xD;
             squamous intraepithelial lesion (AIN2/3 or VIN2/3) diagnosed on or after 1/1/2014;&#xD;
             study pathologist will use p16 staining as needed to rule out low-grade squamous&#xD;
             intraepithelial lesion (LSIL) disease&#xD;
&#xD;
          -  &gt;= 2 months since last therapy for HSIL&#xD;
&#xD;
          -  No clinical evidence of HSIL on screening examination; if HSIL is suspected, a biopsy&#xD;
             will be done to exclude HSIL; patients whose screening visit reveals HSIL on biopsy,&#xD;
             may be re-screened &gt;= 2 months after therapy&#xD;
&#xD;
          -  Resident in the catchment area of the clinics and willing to attend up to 8 clinic&#xD;
             visits for a 36-month period&#xD;
&#xD;
          -  Sexually active women of child-bearing potential must be willing to use effective&#xD;
             contraception through month 7 of the study&#xD;
&#xD;
          -  If human immunodeficiency virus (HIV) positive, receipt of anti-retroviral therapy&#xD;
             continuously for at least 6 months prior to enrollment&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
          -  Willingness to sign medical records release form and tissue release form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Chemotherapy (current, within the last month, or anticipated in the next 7 months)&#xD;
&#xD;
          -  Prior history of invasive HPV-related anogenital cancer (cervical, vaginal, vulvar,&#xD;
             penile, or anal cancer), or oropharyngeal cancer (base of tongue, tonsil); prior&#xD;
             cancer at other sites (including most of oral cavity) or larynx are not exclusions&#xD;
&#xD;
          -  Unstable medical condition (e.g., another malignancy requiring treatment, malignant&#xD;
             hypertension, poorly controlled diabetes, another cancer except for fully excised&#xD;
             non-melanoma skin cancer)&#xD;
&#xD;
          -  Prior HPV vaccination&#xD;
&#xD;
          -  Known allergy or intolerance to lidocaine&#xD;
&#xD;
          -  Currently participating in an interventional research study related to HPV, except the&#xD;
             Anal Cancer HSIL Outcomes Research (ANCHOR) study (NCT02135419)&#xD;
&#xD;
          -  Any other condition which, in the opinion of the investigator, may compromise the&#xD;
             subject's ability to follow study procedures and safely complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>27 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Wald</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UW Virology Research Clinic</last_name>
    <phone>206-520-4340</phone>
    <email>vrc@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Taylor</last_name>
    <phone>206-667-4493</phone>
    <email>sataylor@fredhutch.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warner Huh</last_name>
      <phone>205-934-4696</phone>
      <email>whuh@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Warner Huh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UW Virology Research Clinic</last_name>
      <phone>206-520-4340</phone>
      <email>vrc@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Taylor</last_name>
      <phone>206-667-4493</phone>
      <email>sataylor@fredhutch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Anna Wald</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret Madeleine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2017</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

